Deal-happy Roche acquires Trophos
This article was originally published in Scrip
Executive Summary
In yet another deal, Roche is acquiring rare disease drug developer Trophos at a price of €120m upfront, and a further €350m in potential milestone payments.
You may also be interested in...
Roche Sticking With SMA Despite Terminating Olesoxime
Problems over formulation and the arrival of effective treatment options in spinal muscular atrophy, headed by Biogen's antisense oligonucleotide drug Spinraza, have led to the plug being pulled on olesoxime - but the Swiss major has a back-up candidate.
Horama Joins Race To Develop Gene Therapies For Eye Diseases
Initial VC and institutional funding from a French syndicate will support further drug development at Paris-based Horama, which aims to put two targeted gene therapies for hereditary retinitis pigmentosa in the clinic by 2018.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.